News

Catabasis is prioritizing this program to deliver against its goal of bringing a life changing therapy to those affected by Duchenne. Catabasis CEO Jill Milne said: “This decision

The company's five-year commitment to the fight against malaria was announced in conjunction with the 7th Multilateral Initiative on Malaria Conference and the Malaria Summit of the Commonwealth

Sanofi, which had fully acquired Zentiva in a deal worth about €1.8bn in 2009, is looking to sell it after considering the European generics business to be non-core.

Unigreg owns the rights to Forceval, a micro-nutrient supplement used in pregnancy, in China and some nearby territories. Alliance will continue to market the Forceval brand in the

EMPA-KIDNEY will investigate the effects of empagliflozin on the progression of kidney disease and the occurrence of cardiovascular death, in people with established chronic kidney disease with and

The immuno-oncology combination Opdivo (10mg/mL) and Yervoy (5mg/mL) has been indicated to be intravenously injected in patients with intermediate or poor-risk, advanced RCC, who were previously untreated for

Under the deal, Servier will acquire oncology treatment Oncaspar (pegaspargase), as well as ex-US rights of Onivyde (irinotecan pegylated liposomal formulation). Oncaspar is a component of multi-agent treatment

The company has determined that additional investments of time and resources in these programs are not appropriate given the other opportunities in its product development pipeline. The terminated

Study results showed KEYTRUDA significantly prolonged recurrence-free survival (RFS), reducing the risk of disease recurrence or death by 43% compared to placebo in the overall study population (HR=0.57